Psychedelic Stocks in Focus | Interview with James Lanthier, Mindset Pharma

We had an in-depth interview with James Lanthier, CEO of Mindset Pharma – one of the more interesting psychedelic stocks.  He shared his perspective on: Treatment Resistant Depression (TRD), their plans to synthesize psilocybin, upcoming catalysts and why capital markets are increasing their interest in psychedelic firms.

0 0 votes
Article Rating

The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.

Capital 10X gets down to the real money business, actionable financial insights for traders and investors. We analyze company earnings, interview management teams and help teach the fundamentals of financial analysis and options trading. Our mission is to hunt for genuine 10 baggers.
Notify of
Inline Feedbacks
View all comments